Valuation: TapImmune Inc

Market Cap 21.93M 19.22M 17.72M 16.59M 31.11M 2.07B 31.75M 213M 82.41M 1.02B 82.33M 80.53M 3.54B P/E 2026 *
-1.37x
P/E 2027 * -1.3x
Enterprise Value 21.93M 19.22M 17.72M 16.59M 31.11M 2.07B 31.75M 213M 82.41M 1.02B 82.33M 80.53M 3.54B EV / Sales 2026 *
7.75x
EV / Sales 2027 * 1.09x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 46 2023-04-30
Chief Operating Officer 36 2023-11-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 46 2018-10-16
Chairman 65 2022-05-23
Director/Board Member 62 2019-08-05
Change 5-day change 1-year change 3-year change Capi.($)
+4.17%-12.24% - - 21.93M
+0.94%+7.83%-4.50%+3.17% 46.2B
+2.82%+12.39%+406.54%+610.74% 38.71B
-0.87%+13.15%+20.49%-14.24% 31.9B
+2.64%+5.21%+18.13%+60.12% 31.12B
+8.02%+5.23%+17.67%+35.36% 23.77B
-0.60%+14.40% - - 16.2B
+0.50%+16.84%+69.62%+126.60% 15.05B
-1.13%+7.40%+12.81%+20.67% 13.74B
-0.30%+6.65%+104.85%+96.87% 13.42B
Average +1.60%+10.60%+80.70%+117.41% 25.57B
Weighted average by Cap. +1.55%+10.07%+92.55%+138.07%

Financials

2026 *2027 *
Net sales 2.83M 2.48M 2.29M 2.14M 4.02M 267M 4.1M 27.49M 10.64M 132M 10.63M 10.4M 458M 20.09M 17.61M 16.23M 15.2M 28.5M 1.89B 29.09M 195M 75.5M 936M 75.42M 73.77M 3.25B
Net income -19.36M -16.98M -15.65M -14.65M -27.47M -1.83B -28.04M -188M -72.78M -903M -72.7M -71.12M -3.13B -19.89M -17.44M -16.08M -15.05M -28.22M -1.88B -28.81M -193M -74.77M -927M -74.69M -73.06M -3.22B
Net Debt - -
Logo TapImmune Inc
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-